Florence-based Menarini reports €4.9 billion revenue in 2025

The Florence-based pharmaceutical company Menarini reported revenue of nearly €4.9 billion in 2025, marking a 6.2 percent increase compared with the previous year, as the group continues to expand internationally and invest in research and innovation.

The figures were presented during the company’s annual meeting at the Florence Chamber of Commerce. According to the group, total revenue reached €4.887 billion, with estimated EBITDA between €440 million and €470 million.

Menarini operates in around 140 countries and sold approximately 905 million units of medicines and healthcare products worldwide during the year.

Growing global presence

The company reported solid growth across several regions, particularly in Europe, the Middle East and Central America. The United States has become Menarini’s second-largest market, while China recorded stronger-than-expected results after a weaker performance the previous year.

Some markets remained challenging. The group reported difficulties in Ukraine because of the war and in Turkey due to currency depreciation and inflation. Exchange rate movements also affected the company’s results, with the euro–dollar rate estimated to have reduced revenue by about €60 million.

Women now a majority of employees

Menarini also highlighted changes within its workforce. In 2025, women represented 50.7 percent of the company’s 17,800 employees worldwide, marking the first time that women have become the majority of staff.

The company said the figure reflects its focus on merit-based recruitment and the importance of attracting highly qualified professionals in a competitive global sector.

Strong results in oncology

Several therapeutic areas contributed to the group’s growth, including cardiovascular treatments and medicines for diabetes. Oncology recorded particularly strong results.

Revenue in Menarini’s oncology division increased by €101 million during the year, reaching a total of €630 million. The company said the sector remains one of the most dynamic areas of pharmaceutical research and competition.

Investment in research and technology

Menarini continued to invest heavily in research and development, allocating around €540 million in 2025. The company also invested €120 million in technology and cybersecurity.

As a privately owned, family-controlled company, Menarini said it aims to finance its growth primarily through reinvested profits rather than external funding, allowing it to maintain independence in strategic decisions.

Concerns about European regulation

Company representatives also warned about challenges facing pharmaceutical companies operating in Europe. In particular, they expressed concern about possible changes to the European Union’s rules on patent protection for medicines, which they said could reduce incentives to invest in research.

The group also criticised the proposed European wastewater directive, which would require pharmaceutical companies to contribute to the removal of medicine residues from wastewater. Industry estimates suggest the measure could cost companies across Europe about €12 billion per year.

AI and the future of drug development

Menarini executives said artificial intelligence is becoming an increasingly important tool in pharmaceutical research.

The company is working with the biotechnology firm Insilico Medicine to use AI systems to accelerate the identification of potential drug molecules and support other stages of development, including clinical trials and regulatory processes.

According to the company, the use of artificial intelligence could significantly reduce the time required to develop new medicines. While traditional drug discovery often takes between five and ten years, AI-assisted research could shorten that timeline to two or three years.

Menarini said its current research pipeline includes several projects, including a next-generation treatment aimed at lowering cholesterol and clinical studies involving elacestrant, a drug being studied for the treatment of breast cancer.

❤️ Support Florence Daily News

If you liked this article, please consider supporting Florence Daily News.

We are an independent news site, free from paywalls and intrusive ads, committed to providing clear and reliable reporting on Florence and Tuscany for everyone.

Your support — whether a one-time gift or a regular contribution — helps us stay independent and keep telling the stories that matter.

Donate securely via Stripe below.